Programmed cell death ligand-1 (PD-L1) detection assays have not been standardized for patients with colorectal cancer, and the prognostic value of PD-L1 expression is unclear. We compared the PD-L1 expression patterns in colorectal cancer samples using various immunohistochemical assays using 3 primary PD-L1 antibodies (assay 1, MIH1; assay 2, E1L3; and assay 3, 22C3) and investigated the prognostic implication of PD-L1 expression using each. Additionally, PD-L1 gene amplification was evaluated using FISH. The percentage scorings and positivity rates of the 3 assays differed; the degrees of correlation and concordance between assays 2 and 3 were relatively high, whereas assay 1 was an outlier.
cell receptor signaling and blocking the antitumor immune response. 1 Programmed cell death ligand-1 is upregulated in certain solid tumors; such overexpression can be detected using various immunohistochemical (IHC) assays that recognize different epitopes of PD-L1. As the role of the PD-1/PD-L1 axis in tumor biology has been confirmed, and evidence has emerged that responsiveness to PD-1/PD-L1 inhibitors can be predicted by the intensity of PD-L1 expression, PD-L1 staining using IHC has become a pivotal diagnostic technique. In fact, some PD-L1 IHC assays have been approved by the US FDA as companion or complementary diagnostic tools for the selection of cancer patient candidates eligible for PD-1/PD-L1 inhibitor therapy, including patients with lung and urinary bladder cancer.
The prognostic implication of PD-L1 expression has also been widely researched; its positivity in gastric, esophageal, and pancreatic cancers; glioblastoma; and renal cell carcinoma is reportedly associated with poor clinical outcomes. [2] [3] [4] [5] [6] [7] However, there are conflicting reports regarding the prognostic role of PD-L1 expression in melanomas, lung cancer, and colorectal cancer (CRC). 3, [8] [9] [10] [11] [12] These discrepant results could be attributed, at least partially, to the IHC assays themselves, including the various antibodies and methodologies used in different studies, the absence of a standard cut-off value denoting positivity, and tumor heterogeneity for PD-L1
expression. Amplification of the CD274 gene on chromosome 9p24.1, which encodes PD-L1, has been detected in subgroups of patients with certain malignancies such as Hodgkin's lymphoma, gastric cancer, and triple-negative breast cancer, [13] [14] [15] suggesting that gene amplification might be another method of detecting PD-L1 upregulation.
In this study, we evaluated the prognostic implication of PD-L1 overexpression in CRC. To investigate the methodological variations inherent to IHC assays, 3 different assays and multiple cut-off values for positivity were applied. We aimed to compare the PD-L1 expression patterns across the 3 different IHC assays. Finally, we evaluated the CD274/PD-L1 gene copy number in CRCs using FISH. Histopathologic and clinical data were obtained from the patients' pathological reports and medical records. All CRCs included in our study were diagnosed by a pathologist specializing in lower gastrointestinal tract diseases at our institution (LHS). The presence of lymphatic and vascular invasion was initially evaluated using H&E staining, and equivocal cases were re-evaluated with IHC for CD34
| MATERIALS AND METHODS

| Patients and tissue samples
and D2-40. Pathologic stage was determined per the 7th edition of 
| Construction of tissue microarrays
Slides previously stained with H&E were retrospectively reviewed, and representative formalin-fixed, paraffin-embedded archival blocks were selected for each case. Two cores (2 mm in diameter) extracted from different areas of the tumor were sampled from each tumor specimen using a trephine apparatus. Trephined paraffin tissue cores were consecutively placed into recipient (tissue microarray [TMA]) blocks.
| Immunohistochemistry for PD-L1
Three 4-μm-thick sections were cut from each paraffin TMA block, mounted on positively charged slides, dried, deparaffinized, and 
| Programmed cell death ligand-1 FISH and copy number assessment
Dual color FISH analysis was undertaken on TMA sections. Representative whole tissue sections from the 12 samples that showed immunohistochemical expression of PD-L1 with 2+ or 3+ intensity scores were also subjected to FISH analysis. Four-micrometer sections were cut from paraffin blocks, deparaffinized, dehydrated in 100% alcohol, and air dried. The CD274 (PD-L1)/CEN9q dual color probe (Abnova, Taipei City, Taiwan) was used for in situ hybridization. Dual color probe is a mixture of a red fluorochrome-labeled SPEC CD274 probe that is specific for the CD274 genes on chromosome 9p24.1 and a green fluorochrome-labeled CEN9 probe that is specific for the classical satellite III region of chromosome 9 (D9Z3) at 9q12. At least 50 nuclei per sample were counted. Programmed cell death ligand-1 amplification was defined as a PD-L1/CEP9 ratio ≥2.0; high-level amplification was defined as ≥4.0, and low-level amplification was defined as ≥2.0 and ≤4.0. Polysomy was defined as an average PD-L1 copy number of >3 signals/cell.
| Statistical analysis
All statistical analyses were undertaken using the SPSS version 21.0 software package (IBM, Armonk, NY, USA), and plots were constructed using SigmaPlot (version 6.0) (Merck, Darmstadt, Germany).
Differences between the mean percentage scores of the 3 assays were evaluated using Pearson's χ 2 -test, and Spearman's tests were used to evaluate correlations between the assays. The magnitude of concordance among the 3 assays according to each cut-off was evaluated using the McNemar test. Interobserver agreement between the pathologists was assessed using Cohen's kappa coefficient. The constructed using the Kaplan-Meier method, differences among which were determined using the log-rank test. Multivariate analysis was carried out using Cox's proportional hazards regression model with the backward stepwise selection method. All statistics were 2-sided, and statistical significance was defined as P < .05. the highest mean percentage score was observed using assay 1 (Figure 2B) .
Correlations between the 3 assays are shown in Figure 3 . The Spearman correlation coefficients all showed positive values; however, the absolute correlations between assay 1 and the others were relatively low, whereas the correlation coefficient between assays 2 and 3 was high.
Cytoplasmic expression of PD-L1 was also observed in CRC cells with frequencies of 75.4%, 45.2%, and 0.9% using assays 1, 2, and 3, respectively, with a cut-off value of 1%. was >85% when lower cut-off values (0%, 5%, or 10%) were applied.
| Comparison of positivity rates in the 3 assays according to different cut-off values
The concordance between assays 2 and 3 was >95% using any of (Table S1 ).
F I G U R E 6 CD274/PD-L1 gene amplification by FISH analysis from 2 patients with colorectal cancer. CD274 (red) and CEN9 (green) on chromosome p24.1 (magnification, ×1000). Representative images obtained from the same patients show programmed cell death ligand-1 protein expression in tumor cells (intensity scores: assay 1, 2+; assays 2 and 3, 3+) (magnification, ×200)
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| Expression of PD-L1 in TILs
Representative photographs of PD-L1 staining in TILs using the 3 assays are shown in Figure 1 . A cut-off of 5% was adopted to denote positive staining, as described in a previous study. 16 The PD-L1 positivity rates were 10.3%, 53.7%, and 45.9% when using assays 1, 2, and 3, respectively. The McNemar test revealed significant differences between the positive rates ( Figure 5 ). Expression of PD-L1 in immune and tumor cells was significantly and inversely correlated when using any of the 5 cut-off values in assays 2 and 3, whereas no association was found when using assay 1 (data not shown).
| PD-L1 gene amplification
We further explored the copy number status of the CD274/PD-L1 gene locus using FISH. PD-L1 FISH analysis was carried out in TMA blocks; 1 case had high-level amplification. Subsequently, 12 whole section blocks from CRC samples with intensity scores of 2+ or 3+
in at least 1 of the 3 assays were tested for CD274/PD-L1 gene amplification; this revealed 1 other sample with high gene amplification (PD-L1/CEP ratios = 5.60 and 5.84 in the first and second samples, respectively). Both cases showed strong PD-L1 expression (intensity score = 3+ using both assays 2 and 3) ( Figure 6 ). There were no cases of polysomy. 
| Correlation between PD-L1 expression and clinicopathologic parameters
| Correlation between PD-L1 expression and OS
The mean OS of patients with CRC was 52 months (range, 1-86 months). Among the clinicopathologic parameters, gross type, disease stage, and lymphatic, vascular, and perineural invasion were associated with the patients' OS (P = .005, <.001, <.001, <.001, and <.001, respectively). The expression of PD-L1 in tumor cells was associated with poorer OS (Figure 7A-C) , whereas the expression of PD-L1 in TILs according to assays 2 and 3 was correlated with longer OS (Figure 7D-F) . These correlations were maintained when excluding the 18 patients with MSI-H. (Table 4) .
T A B L E 3 Association between expression of programmed cell death ligand-1 (PD-L1) in colorectal cancer samples and clinicopathologic parameters
PD-L1 in TC PD-L1 in IC N (%) P-value N (%) P-value
Cytoplasmic expression of PD-L1 had no association with patients' OS (data not shown).
| Correlation between PD-L1 expression and DFS
The mean DFS of patients with CRC was 49 months (range, 1-85 months). Among the clinicopathologic parameters, gross type, disease stage, and lymphatic, vascular, and perineural invasion were associated with DFS (P-values: .008, <.001, <.001, <.001, and <.001, respectively). On univariate analysis, the expression of PD-L1
in tumor cells was associated with shorter DFS when using assays 2 and 3; the differences were statistically significant ( Figure 8A-C) . The expression of PD-L1 in TILs was correlated with longer DFS when applying assays 2 and 3 ( Figure 8D-F) . These correlations were maintained when excluding patients with MSI-H.
Multivariate analysis indicated that a high disease stage, positive expression of PD-L1 (assay 3) in tumor cells, and negative expression of PD-L1 (assay 3) in TILs were associated with shorter DFS (Pvalues: <.001, .005, and .002, respectively) ( Table 5 ).
Cytoplasmic expression of PD-L1 had no association with the patients' DFS (data not shown).
| DISCUSSION
Previous studies revealed an association between unfavorable clinical outcomes and tumoral PD-L1 expression in patients with CRC, 11, 17, 18 whereas other studies found no such associations. 9, 19 Some researchers suggested that the prognostic implication of PD-L1 expression might depend on the mismatch repair status, TILs are independent of the number of T cells; in our previous study, there was no evidence that PD-L1 expression was related to the density of TILs. 19 The complex interaction between immune effector cells and the tumor microenvironment very likely impacts the biological significance of particular immune markers and also appears to be dependent on the tumor type.
We compared the staining patterns of 3 different primary antibodies in CRC tissues and used various cut-off values for positivity.
Although the percentage scores and positivity rates of the 3 assays were significantly different, the degree of correlation and concordance rate between assays 2 and 3 were relatively high. This was similar to the results of Rimm et al. 26 However, the degrees of correlation between assay 1 and the other assays were low; moreover, the concordance rates between assays 1 and 2 or between assays 1 and 3 decreased when applying higher cut-off values. Assay 1 was also an outlier in terms of percentage scores and positivity rates.
The PD-L1 positivity rates in CRCs varied in previous studies; a study using MIH1 as the primary PD-L1 antibody found very high PD-L1 positivity rates in CRC tumor cells but concluded that there was no prognostic significance for PD-L1 expression. 9 Similarly, we found a lower level of statistical significance between PD-L1 expression and prognosis when applying assay 1. The cytoplasmic expression levels in each of the 3 assays were also different, and interobserver discrepancies in membranous staining were high for assays 1 and 2, which showed higher frequencies of cytoplasmic expression, implying that the cytoplasmic staining pattern might distort the interpretation of membranous staining. These results revealed the influence of the type of IHC assay on outcomes. Copy number gains could be responsible for increased expression levels of genes located at the gained locus; in the present study, amplification is used for determining trastuzumab candidates in gastric and breast cancers when HER-2 expression is inconclusive on IHC. It might be worthwhile to determine whether PD-L1 copy numbers are associated with clinical improvement following anti-PD-1/ PD-L1 therapy in CRC patients.
There were some limitations in our study. First, we had no outcome data as our patients were not treated with PD-1/PD-L1 inhibitor therapy; hence, the direct relationship between PD-L1 expression and response to such inhibitors could not be evaluated.
Second, the number of CRC cases with MSI-H in our cohort was relatively small, and none of the patients with MSI-H died during the follow-up period. Thus, evaluating the clinical implication of PD-L1 expression in patients with MSI-H was not possible. Finally, the possibility of bias from intratumoral heterogeneity was not completely ruled out, although 2 cores per tumor were acquired.
In conclusion, we showed that PD-L1 expression in tumors and 
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